USA News Group – A new study is bringing hope in the fight against one of the deadliest cancers, revealing a blood test that can detect early-stage pancreatic cancer with 97% accuracy. This breakthrough...
EQNX::TICKER_START (ONASDAQ:ONCY),(TSX:ONC),(NASDAQ:BLRX),(NASDAQ:IMRX),(NASDAQ:CADL) EQNX::TICKER_END
Immuneering is ready to share information regarding its lead therapy.
Pyramid Biosciences, Inc., a Boston-based, clinical-stage, biotechnology company focused on developing new and highly differentiated precision therapies for cancer, today announced the expansion of its...
CAMBRIDGE, Mass., July 06, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company using translational...
IMM-1-104 strongly inhibits tumor growth in an animal model of KRAS-G12V mutant pancreatic cancer Preclinical data package now includes animal studies...
CAMBRIDGE, Mass., May 20, 2022 (GLOBE NEWSWIRE) -- Â Immuneering Corporation (NASDAQ: IMRX), a biopharmaceutical company using translational...
IND filing for IMM-1-104 expected in Q3 2022; Enrollment of the first patient expected in Q4 2022Â IND filing for IMM-6-415, designed to sensitize...
CAMBRIDGE, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company using translational bioinformatics...
CAMBRIDGE, Mass., April 01, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company using translational...